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Abstract
The surveillance of neurosyphilis, an uncommon but severe consequence of syphilis, is complex; 
surveillance classification of neurosyphilis requires a lumbar puncture and cerebrospinal fluid 
analysis. We examined the prevalence of reported neurosyphilis among primary, secondary, and 
early latent syphilis cases reported in the United States from 2009 to 2015. Overall, the prevalence 
of reported neurosyphilis from 2009 to 2015 was low (0.84%); however, this is likely an 
underestimate of the true burden in the United States.
BACKGROUND
In the United States, the rate of primary and secondary (P&S) syphilis has increased almost 
every year since 2001.1 As rates of P&S syphilis increase, a likely consequence will be a 
parallel increase in the prevalence of adverse health outcomes associated with syphilitic 
infection such as neurosyphilis. In recent years, several large urban areas in the United 
States have reported increases in neurosyphilis; however, it is unknown whether these 
reports are representative of a national trend in neurosyphilis or whether the incidence of 
neurosyphilis is proportional to what would be expected given the overall increase in early 
syphilis rates.2–6
Neurosyphilis is an uncommon but severe consequence of syphilis and can occur at any 
stage of infection.7 The diagnosis of neurosyphilis is complex. The clinical diagnosis of 
neurosyphilis depends on an evaluation of neurologic signs and symptoms, and results from 
serologic and cerebrospinal fluid (CSF) tests (including CSF cell count, protein, and CSF 
Venereal Disease Research Laboratory [CSF-VDRL]).7 Current Centers for Disease Control 
and Prevention (CDC) sexually transmitted disease treatment guidelines recommend 
performing a lumbar puncture and CSF analysis for patients infected with syphilis who 
display clinical signs of neurosyphilis (e.g., cranial nerve dysfunction, auditory or 
ophthalmic abnormalities, meningitis, stroke, acute or chronic altered mental status, and loss 
of vibration sense).7 Syphilis is a nationally notifiable condition, and neurosyphilis should 
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be reported to CDC.1 In light of the limited availability of population-based data on 
neurosyphilis in the United States, we aimed to examine national case report data to describe 
the prevalence and epidemiology of reported neurosyphilis among primary, secondary, and 
early latent syphilis (“early syphilis”) cases reported in the United States from 2009 to 2015.
METHODS
We examined early syphilis case data reported to the National Notifiable Diseases 
Surveillance System at the CDC from 2009 to 2015, which include limited demographic and 
clinical information and whether neurosyphilis was present. Neurosyphilis is reported as 
confirmed, probable, no, or unknown. For surveillance purposes, “confirmed neurosyphilis” 
is defined as syphilis of any stage with a reactive CSF-VDRL test and either a reactive 
treponemal serologic test for syphilis or a reactive nontreponemal test for syphilis. “Probable 
neurosyphilis” is defined as syphilis of any stage with a negative CSF-VDRL test result and 
either a reactive treponemal serologic test for syphilis or a reactive nontreponemal serologic 
test for syphilis, an elevated CSF protein or leukocyte count, and clinical symptoms or signs 
consistent with neurosyphilis in the absence of other known causes for these abnormalities. 
We compared the prevalence of reported confirmed and probable neurosyphilis in 2015 
among all early syphilis cases by sex, sex of sex partner, race/ethnicity (as defined by Office 
of Management and Budget standards), age group, and reported HIV status. When 
examining trends from 2009 to 2015, we limited our analysis to early syphilis cases reported 
from 10 states that, from 2009 to 2015, consistently reported data on neurosyphilis 
(confirmed, probable, or no) for at least 70% of total early syphilis cases reported. Data 
analyses were conducted using SAS version 9.3 (SAS Institute, Inc, Cary, NC).
RESULTS
In 2015, a total of 48,045 cases of early syphilis were reported to CDC from the 50 US 
states and the District of Columbia. Of these, there were 403 (0.8%) cases with 
neurosyphilis reported: 295 (0.6%) with confirmed neurosyphilis and 108 (0.2%) with 
probable neurosyphilis (Table 1). The prevalence of reported neurosyphilis was highest 
among those with secondary syphilis (1.1%) compared with those with primary (0.3%) or 
early latent syphilis (0.8%). Men with early syphilis had a higher prevalence (0.9%) 
compared with women with early syphilis (0.5%). Among men, the prevalence of reported 
neurosyphilis was highest among men who have sex with both men and women (1.4%) 
compared with men who have sex with men (MSM) only (0.9%), men with an unknown sex 
of sex partner (0.8%), and men who have sex with women only (0.7%). Whites with early 
syphilis had a higher prevalence of reported neurosyphilis (1.2%) compared with blacks 
(0.9%), Hispanics (0.5%), and persons reporting an “other” or multiple-race categories 
(0.4%). The prevalence of reported neurosyphilis among those 0 to 14 years old was 2.0%, 
with 1 case of neurosyphilis reported among 50 early syphilis cases, 1.2% (n = 225) among 
those 35 to 64 years old, 1.1% (n = 5) among those 65 years and older, and 0.6% (n = 172) 
among those 15 to 34 years old. The prevalence of reported neurosyphilis was higher among 
persons with early syphilis who were known to be living with diagnosed HIV (1.2%) 
compared with those who were HIV negative (0.7%).
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From 2009 to 2015, all 50 US states and the District of Columbia reported 1 or more cases 
of early syphilis. Ten states consistently reported data on neurosyphilis for at least 70% of 
early syphilis cases from 2009 to 2015 (Delaware, Georgia, Hawaii, Indiana, Kentucky, 
Maine, South Dakota, Texas, Virginia, and West Virginia). The percentage of total reported 
neurosyphilis cases accounted for by these 10 states varied from 2009 to 2015 but ranged 
from 19.3% in 2014 to 39.5% in 2015. Among these 10 states, the overall prevalence of 
reported neurosyphilis among reported cases of early syphilis from 2009 to 2015 was 1.8% 
(Fig. 1). Among persons reported with early syphilis, the annual prevalence of reported 
neurosyphilis varied over the study period (Fig. 1), with a relative decrease in the prevalence 
of reported neurosyphilis in 2014 (0.8%) and in 2015 (1.8%) when compared with 2013 
(2.5%).
DISCUSSION
Neurosyphilis is an uncommon but serious complication of syphilitic infection that can 
involve persistent disabilities for patients. As rates of syphilis increase in the United States,1 
it is essential to continue to monitor trends in complicated syphilitic infections such as 
neurosyphilis. In summary, the results from our examination of national case report data 
indicate that the prevalence of reported neurosyphilis among early syphilis cases varied from 
2009 to 2015, but that the overall prevalence remained low. Our prevalence estimate of 1.8% 
is comparable to earlier cohort prevalence estimates on the basis of retrospective health 
record reviews of MSM in the United States, which ranged from 1.2% to 1.7%.3,4 In 2015, 
compared with other groups, there was a higher prevalence of reported neurosyphilis among 
male and white patients with early syphilis, as well as among patients with early syphilis 
known to be living with diagnosed HIV.
Our use of national case report data to examine the prevalence of neurosyphilis is 
strengthened by the use of a standardized surveillance case definition for neurosyphilis. 
However, there are a number of challenges associated with the surveillance of neurosyphilis 
that can result in case reports underestimating the true burden of disease. First, variations in 
clinical practice, including variability in screening for neurologic signs and symptoms and 
variability in use of lumbar puncture to evaluate patients with neurologic signs or symptoms, 
likely lead to underascertainment of syphilis cases that meet the surveillance case definition 
of neurosyphilis. Because the surveillance case definition for both probable and confirmed 
neurosyphilis requires documentation of abnormal CSF results, clinical settings that have a 
higher clinical threshold for performing lumbar punctures or that treat a patient for 
neurosyphilis without performing a lumbar puncture will be less likely to have a case that 
meets the surveillance case definition of neurosyphilis. Second, variations in health 
department practices, namely, variability in the extent to which reported early syphilis cases 
are followed up with provider or patient interviews to identify cases that might meet the 
neurosyphilis surveillance case definition, might lead to underascertainment and 
underreporting of neurosyphilis cases.
This variation in successful contact of the patient or provider has implications for the 
interpretation of a “no” or “unknown” response when reporting neurosyphilis and limits our 
ability to disentangle patients who were not successfully contacted from patients whose 
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neurosyphilis was ruled out. Because both “no” and “unknown” reports were included in our 
denominator when calculating prevalence, we are likely underestimating the true burden of 
disease. Changes in neurosyphilis screening and reporting practices over time could result in 
an increase or decrease in reported cases, which would not be reflective of a true change in 
incidence. Standardized monitoring of neurosyphilis screening practices by jurisdictions 
could help to better inform the interpretation of trends in surveillance data.
Our findings are subject to a few limitations. We found a higher prevalence of neurosyphilis 
among persons known to be living with diagnosed HIV compared with persons who were 
HIV negative or with an unknown HIV status. This finding may be subject to ascertainment 
bias and could be reflecting a higher likelihood of HIV-infected persons being screened for 
signs or symptoms of neurosyphilis. There have, however, been studies suggesting that 
immunocompromised persons may have a higher risk for developing neurosyphilis, even 
after appropriate treatment and declines in serum rapid plasma reagin.8,9 This is further 
complicated by the fact that almost 90% of reported early syphilis cases in 2015 were among 
MSM and reported cases of P&S syphilis continue to be characterized by a high rate of HIV 
coinfection.1 Furthermore, our trend analysis was limited to early syphilis cases reported 
from 10 states that, from 2009 to 2015, consistently reported data on neurosyphilis for at 
least 70% of total early syphilis cases. Early syphilis cases from these jurisdictions may not 
be representative of all persons who received a diagnosis of early syphilis in the United 
States from 2009 to 2015.
In conclusion, these are the first national prevalence estimates of reported neurosyphilis 
among early syphilis cases in the United States. These estimates are based on case report 
data and therefore subject to the inherent limitations of passive, case-based surveillance data. 
These estimates likely underestimate the true burden of neurosyphilis in the United States 
and are subject to variations in screening and diagnostic practices across jurisdictions. 
Possible ways to improve the surveillance of neurosyphilis could include the routinized 
clinical assessment of neurologic signs and symptoms among all diagnosed syphilis cases, 
which along with complete clinical data from reporting providers could help strengthen the 
ascertainment of neurosyphilis among reported syphilis cases by health departments. 
Because the prevalence of syphilis is increasing in the United States, we can expect to see an 
increase in the number of cases of complicated syphilis. Education and training of providers 
to be able to recognize signs and symptoms of neurosyphilis as early as possible and manage 
disease sequelae are critical.
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Figure 1. 
Early syphilis—reported cases and prevalence of neurosyphilis by year, from 10 states†, 
2009 to 2015.
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